Arbutus doses first patient in additional treatment arm of phase 2a triple combination clinical trial that includes a pd-1 monoclonal antibody

Evaluating safety and efficacy of combining ab-729, vtp-300, nucleos(t)ide analogues and nivolumab (opdivo®) warminster, pa., june 21, 2023 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus) (“arbutus” or the “company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the first patient has been dosed in the additional treatment arm of the ab-729 phase 2a triple combination clinical trial that has been expanded to include a pd-1 monoclonal antibody, nivolumab.
ABUS Ratings Summary
ABUS Quant Ranking